Connected Health Technology for Cardiovascular Disease Prevention and Management
Purpose of the review
Advances in computing power and wireless technologies have reshaped our approach to patient monitoring. Medical grade sensors and apps that were once restricted to hospitals and specialized clinic are now widely available. Here, we review the current evidence supporting the use of connected health technologies for the prevention and management of cardiovascular disease in an effort to highlight gaps and future opportunities for innovation.
Initial studies in connected health for cardiovascular disease prevention and management focused primarily on activity tracking and blood pressure monitoring but have since expanded to include a full panoply of novel sensors and pioneering smartphone apps with targeted interventions in diet, lipid management and risk assessment, smoking cessation, cardiac rehabilitation, heart failure, and arrhythmias. While outfitting patients with sensors and devices alone is infrequently a lasting solution, monitoring programs that include personalized insights based on patient-level data are more likely to lead to improved outcomes. Advances in this space have been driven by patients and researchers while healthcare systems remain slow to fully integrate and adequately adapt these new technologies into their workflows.
Cardiovascular disease prevention and management continue to be key focus areas for clinicians and researchers in the connected health space. Exciting progress has been made though studies continue to suffer from small sample size and limited follow-up. Efforts that combine home patient monitoring, engagement, and personalized feedback are the most promising. Ultimately, combining patient-level ambulatory sensor data, electronic health records, and genomics using machine learning analytics will bring precision medicine closer to reality.
KeywordsMobile health Digital medicine Innovation
Shannon Wongvibulsin is supported by the Johns Hopkins School of Medicine Medical Scientist Training Program (National Institutes of Health: Institutional Predoctoral Training Grant - T32), National Institutes of Health: Ruth L. Kirschstein Individual Predoctoral NRSA for MD/PhD: F30 Training Grant, and the Johns Hopkins Individualized Health (inHealth) Initiative. Evan D. Muse and Steven R. Steinhubl are supported by the NCATS/NIH of The Scripps Research Institute (UL1TR002550).
Compliance with Ethical Standards
Conflict of Interest
Shannon Wongvibulsin, Steven R. Steinhubl, and Evan D. Muse each declare no potential conflicts of interest.
Seth S. Martin serves on the scientific advisory boards of Amgen, Sanofi, Regeneron, Esperion, Novo Nordisk, Quest Diagnostics, and Akcea Therapeutics and reports grants from Apple, Google, iHealth, Nokia, Maryland Innovation Initiative, American Heart Association, Aetna Foundation, P J Schafer Memorial Fund, and David and June Trone Family Foundation. Dr. Martin reports a patent pending filed by Johns Hopkins as a co-inventor for a method of LDL-C estimation. Dr. Martin is a founder of and holds equity in Corrie Health, which intends to further develop the platform. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart disease and stroke statistics—2018 update: a report from the American Heart Association. Circulation 2018;137(12).Google Scholar
- 5.• Byambasuren O, Sanders S, Beller E, Glasziou P. Prescribable mHealth apps identified from an overview of systematic reviews. NPJ Digit Med. 2018;1(1):12 In an effort to identify “prescribable” health apps, this evaluation of systematic reviews illustrates the current gaps in evidence from high quality clinical studies.CrossRefGoogle Scholar
- 6.• Noah B, Keller MS, Mosadeghi S, Stein L, Johl S, Delshad S, et al. Impact of remote patient monitoring on clinical outcomes: an updated meta-analysis of randomized controlled trials. Npj Digit Med. 2018;1(1):20172 Updated meta-analysis of clinical trials assessing wearable sensors highlighting the importance of behavior change and coaching for targeted interventions.CrossRefGoogle Scholar
- 9.Mclean G, Band R, Saunderson K, Hanlon P, Murray E, Little P, et al. Digital interventions to promote self-management in adults with hypertension systematic review and meta-analysis. 2016.Google Scholar
- 13.• Morawski K, Ghazinouri R, Krumme A, Lauffenburger JC, Lu Z, Durfee E, et al. Association of a smartphone application with medication adherence and blood pressure control. JAMA Intern Med. 2018;178(6):802 In this study, individuals with hypertension received home blood pressure monitors and were randomized to the use of a novel smartphone application to promote mediation adherence. Despite these interventions, no improvement in blood pressure was achieved.PubMedPubMedCentralCrossRefGoogle Scholar
- 16.• McManus RJ, Mant J, Franssen M, Nickless A, Schwartz C, Hodgkinson J, et al. Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial. Lancet (London, England). 2018;391(10124):949–59 Pivotal trial for home blood pressure monitoring illustrating benefits over traditional (clinical) blood pressure monitoring in the ambulatory setting.CrossRefGoogle Scholar
- 17.Margolis KL, Asche SE, Dehmer SP, Bergdall AR, Green BB, Sperl-Hillen JM, et al. Long-term outcomes of the effects of home blood pressure telemonitoring and pharmacist management on blood pressure among adults with uncontrolled hypertension. JAMA Netw Open. 2018;1(5):e181617.PubMedPubMedCentralCrossRefGoogle Scholar
- 32.Martin SS, Feldman DI, Blumenthal RS, Jones SR, Post WS, McKibben RA, et al. mActive: a randomized clinical trial of an automated mHealth intervention for physical activity promotion. J Am Heart Assoc. 2015;4(11).Google Scholar
- 34.• Finkelstein EA, Haaland BA, Bilger M, Sahasranaman A, Sloan RA, Nang EEK, et al. Effectiveness of activity trackers with and without incentives to increase physical activity (TRIPPA): a randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4(12):983–95 A large-scale evaluation of the use of positive incentive strategies (cash or charitable donations) to increase physical activity. Despite improvements in activity with either incentive, there were no changes in health outcomes.PubMedCrossRefGoogle Scholar
- 38.• Chokshi NP, Adusumalli S, Small DS, Morris A, Feingold J, Ha YP, et al. Loss-framed financial incentives and personalized goal-setting to increase physical activity among ischemic heart disease patients using wearable devices: the ACTIVE REWARD randomized trial. J Am Heart Assoc. 2018;7(12). In a CV high-risk cohort, this study investigated loss-framed incentives (in contrast to TRIPPA which used positive incentives) to promote healthy behaviors.Google Scholar
- 45.O’Sullivan A, Henrick B, Dixon B, Barile D, Zivkovic A, Smilowitz J, et al. 21st century toolkit for optimizing population health through precision nutrition. Crit Rev Food Sci Nutr. 2017 Jul;5:1–12.Google Scholar
- 49.• Liao Y, Wu Q, Kelly BC, Zhang F, Tang Y-Y, Wang Q, et al. Effectiveness of a text-messaging-based smoking cessation intervention (“Happy Quit”) for smoking cessation in China: a randomized controlled trial. Degenhardt L, editor. PLOS Med. 2018;15(12):e1002713 This study, done exclusively in China, showed clinical efficacy of a cognitive behavioral therapy based text-messaging approach for smoking cessation.PubMedPubMedCentralCrossRefGoogle Scholar
- 51.Vidrine DJ, Frank-Pearce SG, Vidrine JI, Tahay PD, Marani SK, Chen S, et al. Efficacy of mobile phone–delivered smoking cessation interventions for socioeconomically disadvantaged individuals. JAMA Intern Med. 2018.Google Scholar
- 61.• Volpp KG, Troxel AB, Mehta SJ, Norton L, Zhu J, Lim R, et al. Effect of electronic reminders, financial incentives, and social support on outcomes after myocardial infarction. JAMA Intern Med. 2017;177(8):1093 An inventive study that utilized a combination approach consisting of financial incentives, electronic pill bottles, and social support to promote medication adherence, yet resulting in no significant improvements. Highlights the complex issues regarding behavior change.PubMedPubMedCentralCrossRefGoogle Scholar
- 70.De La I, Díez T, Garcia-Zapirain B, Méndez-Zorrilla A, López-Coronado M. Monitoring and follow-up of chronic heart failure: a literature review of eHealth applications and systems.Google Scholar
- 72.Pereira VFA, Valentin LSS. The MentalPlus® digital game might be an accessible open source tool to evaluate cognitive dysfunction in heart failure with preserved ejection fraction in hypertensive patients: a pilot exploratory study. Int J Hypertens. 2018;2018.Google Scholar
- 73.• Koehler F, Koehler K, Deckwart O, Prescher S, Wegscheider K, Kirwan B-A, et al. Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. Lancet (London, England). 2018;392(10152):1047–57 This study combined home telemonitoring sensor technologies (BP, bodyweight, heart rate and rhythm, SpO2) with tailored, patient-specific interventions that resulted in a reduction of days lost due to CV hospitalizations and all-cause mortality.CrossRefGoogle Scholar
- 74.Support-hf, Investigators, Committees. Home monitoring with IT-supported specialist management versus home monitoring alone in patients with heart failure: design and baseline results of the SUPPORT-HF 2 randomized trial SUPPORT-HF 2 Investigators and Committees 1 Trial Designs. 2018.Google Scholar
- 79.Kotecha D, Chua WWL, Fabritz L, Hendriks J, Casadei B, Schotten U, et al. European Society of Cardiology smartphone and tablet applications for patients with atrial fibrillation and their health care providers. EP Eur. 2018;20(2):225–33.Google Scholar
- 82.Golzar M, Fotouhi-Ghazvini F, Rabbani H, Zakeri FS. Mobile cardiac health-care monitoring and notification with real time tachycardia and bradycardia arrhythmia detection. J Med Signals Sens. 7(4):193–202.Google Scholar
- 84.Chan P, Wong C, Poh YC, Pun L, Leung WW, Wong Y, et al. Diagnostic performance of a smartphone-based photoplethysmographic application for atrial fibrillation screening in a primary care setting. J Am Heart Assoc. 2016;5(7).Google Scholar
- 89.• Steinhubl SR, Waalen J, Edwards AM, Ariniello LM, Mehta RR, Ebner GS, et al. Effect of a home-based wearable continuous ECG monitoring patch on detection of undiagnosed atrial fibrillation. JAMA. 2018;320(2):146 While this study reported a creative screening strategy for individuals at high risk of atrial fibrillation, a key aspect here is the complete digitization of the clinical trial operations from start to finish.PubMedCrossRefGoogle Scholar
- 93.• Tison GH, Sanchez JM, Ballinger B, Singh A, Olgin JE, Pletcher MJ, et al. Passive detection of atrial fibrillation using a commercially available smartwatch. JAMA Cardiol. 2018;3(5):409 This was one of the first studies to combine a smartwatch assessment of cardiac rhythm with deep-learning analytics illustrating the challenges of rhythm prediction in an ambulatory setting.PubMedPubMedCentralCrossRefGoogle Scholar
- 100.Kim J, Campbell AS, de Ávila BE-F, Wang J. Wearable biosensors for healthcare monitoring. Nat Biotechnol. 2019;1.Google Scholar